Search Result

Results for "

FXR+agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminotransferases (Transaminases) (1) AMPK (1) Antibiotic (1) Autophagy (15) Bacterial (1) Cytochrome P450 (2) Drug Metabolite (2) Endogenous Metabolite (1) FXR (63) G protein-coupled Bile Acid Receptor 1 (2) HBV (1) Heme Oxygenase (HO) (1) Insecticide (2) Isotope-Labeled Compounds (5) Keap1-Nrf2 (1) PD-1/PD-L1 (1) Phosphatase (1) PPAR (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (2) Reference Standards (5) TNF Receptor (2)
By Research Areas:	Cancer (5) Cardiovascular Disease (3) Infection (4) Inflammation/Immunology (34) Metabolic Disease (27)

By Targets:

Aminotransferases (Transaminases) (1)

AMPK (1)

Antibiotic (1)

Autophagy (15)

Bacterial (1)

Cytochrome P450 (2)

Drug Metabolite (2)

Endogenous Metabolite (1)

FXR (63)

G protein-coupled Bile Acid Receptor 1 (2)

HBV (1)

Heme Oxygenase (HO) (1)

Insecticide (2)

Isotope-Labeled Compounds (5)

Keap1-Nrf2 (1)

PD-1/PD-L1 (1)

Phosphatase (1)

PPAR (1)

Quinone Reductase (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (5)

TNF Receptor (2)

By Research Areas:

Cancer (5)

Cardiovascular Disease (3)

Infection (4)

Inflammation/Immunology (34)

Metabolic Disease (27)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50108

GW 4064 55+ Cited Publications	FXR Autophagy	Metabolic Disease Cancer
GW 4064 is a potent *FXR* agonist with an EC₅₀ of 65 nM.

HY-12222

Obeticholic acid Maximum Cited Publications 85 Publications Verification INT-747; 6-ECDCA; 6-Ethylchenodeoxycholic acid	FXR Autophagy	Others
Obeticholic acid (INT-747) is a potent, selective and orally active *FXR* agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-10912

Fexaramine 5+ Cited Publications	FXR Autophagy	Others
Fexaramine is a potent and selective *FXR* agonist with an EC₅₀ of 25 nM. Fexaramine has no activity against hRXRα, hPPARαγδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ, and hVDR receptors .

HY-109083

Cilofexor 5+ Cited Publications GS-9674	FXR Autophagy	Inflammation/Immunology
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal *FXR* agonist with an EC₅₀ of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .

HY-N4067

Isochenodeoxycholic acid isoCDCA	FXR Endogenous Metabolite	Metabolic Disease
Isochenodeoxycholic acid (isoCDCA) is a *FXR* agonist. Isochenodeoxycholic acid activates the activity of FXR and induces the mRNA expression of FXR target genes (Ostβ and Kng1). Isochenodeoxycholic acid serves as a substrate for the liver class I ADH γγ isozyme-mediated 3β-dehydrogenation reaction .

HY-50911

Turofexorate isopropyl 3 Publications Verification FXR-450; XL335; WAY-362450	FXR Autophagy	Metabolic Disease Cancer
Turofexorate isopropyl (FXR-450) is a potent, selective, and orally bioavailable *FXR* agonist with EC₅₀ of 4 nM .

HY-109197

Vonafexor 2 Publications Verification EYP001	FXR HBV	Infection
Vonafexor (EYP001) is an orally active, non-steroidal and selective *FXR* agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research .

HY-160929

Linafexor CS-0159	FXR	Inflammation/Immunology
Linafexor (CS-0159) is a *FXR* agonist and bile acid homeostasis modulator. Linafexor exerts its effects by activating FXR, a regulator of liver function. Linafexor is applicable to research related to primary sclerosing cholangitis (PSC). Linafexor is also suitable for research in the field of metabolic dysfunction-associated steatohepatitis (MASH) .

HY-151932

FXR agonist 3 1 Publications Verification	FXR	Inflammation/Immunology
FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .

HY-N3431

Kaempferol-7-O-rhamnoside	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)	Cardiovascular Disease
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-109096

Nidufexor LMB763	FXR Autophagy	Inflammation/Immunology
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH) .

HY-147296

Omesdafexor MET409	FXR	Inflammation/Immunology Cancer
Omesdafexor (MET409) is an orally active *FXR* agonist with a unique non-bile acid structure. Omesdafexor can be used for the study of non-alcoholic steatohepatitis (NASH) .

HY-N4294

Arjungenin	FXR Insecticide	Infection Metabolic Disease Inflammation/Immunology
Arjungenin, a pentacyclic triterpenoid compound, is a *FXR* agonist. Arjungenin can improve insulin sensitivity by regulating the function of fat cells. Arjungenin exhibits moderate free radical scavenging activity. Arjungenin has growth inhibitory activity against the insect Spilarctia obliqua. Arjungenin has significant antiviral activity against a series of viruses such as chikungunya Virus (CHIKV) .

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

HY-151959

FXR agonist 4	FXR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-169792

HPG1860	FXR Aminotransferases (Transaminases)	Metabolic Disease Inflammation/Immunology
HPG1860 is an orally active, highly selective and potent *FXR* agonist, with an EC₅₀ of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC₅₀ values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .

HY-135399

Tauro-obeticholic acid	FXR	Inflammation/Immunology
Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-164799

FXR agonist 12	FXR	Inflammation/Immunology
FXR agonist 12 (Compound C7) is the orally active agonist for FXR. FXR agonist 12 down-regulates bile acid synthesis-related genes, and up-regulates bile acid transport-related genes in HepG2 cells. FXR agonist 12 improves ANIT-induced cholestasis, ameliorates the liver damage and fibrosis in mouse NASH models .

HY-N3209

Nelumol A	FXR	Inflammation/Immunology
Nelumol A is a farnesoid X receptor (FXR) agonist .

HY-103704

LY2562175	FXR Autophagy	Metabolic Disease
LY2562175 is a potent and selective *FXR* agonist, with an EC₅₀ of 193 nM .

HY-N3891

Fargesone A	FXR	Inflammation/Immunology
Fargesone A is a potent and selective *FXR* agonist. Fargesone A shows anti-inflammatory activity .

HY-100443A

trans-PX20606 3 Publications Verification trans-PX-102	FXR Autophagy	Metabolic Disease
PX20606 trans racemate (PX-102 trans racemate) is a *FXR* agonist with EC₅₀s of 32 and 34 nM for FXR in FRET and M1H assay, respectively .

HY-12222R

Obeticholic acid (Standard) INT-747 (Standard); 6-ECDCA (Standard); 6-Ethylchenodeoxycholic acid (Standard)	Reference Standards FXR Autophagy	Others
Obeticholic acid (Standard) is the analytical standard of Obeticholic acid. This product is intended for research and analytical applications. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-139418

PX20350	FXR	Cancer
PX20350 is a *FXR* agonist with EC₅₀s of 83 and 10 nM for mFXR and hFXR, respectively. PX20350 significantly induces NDRG2 mRNA expression. PX20350 potently reduces liver tumor cells (SK-GI-18 cells) growth and metastasis, and has anti-tumorigenic activity in orthotopic xenograft mouse models .

HY-153525

FXR agonist 5	FXR	Metabolic Disease Inflammation/Immunology
FXR agonist 5 (compound 1) is a *FXR* agonist. FXR agonist 5 can be used for research in diseases or disorders caused by metabolic inflammation .

HY-W587537

Deoxycholic acid 3-O-β-D-glucuronide disodium	FXR	Metabolic Disease
Deoxycholic Acid 3-O-beta-D-Glucuronide disodium salt is a bile acid receptor (FXR) agonist.

HY-168332

FXR agonist 11	FXR	Metabolic Disease
FXR agonist 11 (Compound 14) is an *FXR* agonist with an EC₅₀ of 1.2 μM and a maximum effect of 73.7%. FXR agonist 11 can significantly increase GSH levels in the liver and is used to study drug-induced liver injury diseases .

HY-178959

FXR agonist 13	FXR	Metabolic Disease Inflammation/Immunology
FXR agonist 13 is a selective, orally active, potent *FXR* agonist (EC₅₀ = 0.097 μM) and has favorable hepatic microsomal metabolic stability. FXR agonist 13 exhibits moderate affinity for FXR-LBD upon direct binding (K_D = 14.74 μM). FXR agonist 13 displays good selectivity against related nuclear receptors, including LXRα/β, PPARα/γ/δ, PXR, and TGR5. FXR agonist 13 can be used for the study of metabolic-associated steatohepatitis (MASH) .

HY-163466

FXR agonist 7	FXR	Inflammation/Immunology
FXR agonist 7 (compound 33) is a potent agonist of FXR, with EC₅₀ of 0.1 nM. FXR agonist 7 shows high intestinal distribution, good anti-inflammatory activity .

HY-N10640

Alismanol M	FXR	Inflammation/Immunology
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .

HY-W587451

Cholic acid 3-O-glucuronide disodium OCA-3-glucuronide disodium	FXR	Metabolic Disease
Cholic acid 3-O-glucuronide (OCA-3-glucuronide) disodium is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 91.5 μM. Cholic acid 3-O-glucuronide is promising for research of bile acid metabolism and detoxification .

HY-12222S

Obeticholic acid-d5 INT-747-d₅; 6-ECDCA-d₅; 6-Ethylchenodeoxycholic acid-d₅	FXR Autophagy	Others
Obeticholic acid-d₅ is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-113567

GSK2324	FXR	Metabolic Disease
GSK2324 (Compd 1c) is a *FXR* agonist for diabetes study, with an EC₅₀ of 120 nM. GSK2324 exhibits t_1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively .

HY-168629

FXR agonist 9	FXR	Metabolic Disease
FXR agonist 9 (compound 26) is an oral active and selectivity FXR partial agonist with the EC₅₀ of 0.09 µM (75.13 % maximum efficacy). FXR agonist 9 ameliorates pathological features in HFD and CCl₄(HY-Y0298)-induced metabolic dysfunction-associated steatohepatitis mice .

HY-153114

HEC96719	FXR	Inflammation/Immunology
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC₅₀ values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .

HY-50108A

(E)-GW 4064	FXR	Others
(E)-GW 4064 is a *FXR* agonist .

HY-159845

Lecufexor	FXR	Metabolic Disease
Lecufexor is a farnesoid X receptor (FXR) agonist .

HY-181761

FXR agonist 16	FXR	Metabolic Disease
FXR agonist 16 is a *FXR* agonist with an EC₅₀ of 2.2 μM. FXR agonist 16 activates FXR transcriptional activity, upregulates SHP and BSEP, and downregulates Cyp7a1. FXR agonist 16 exhibits hepatoprotective activity and reduces AST and ALT levels in free fatty acid-induced hepatocellular injury models. FXR agonist 16 can be used for the research of liver injury .

HY-135400

Glyco-Obeticholic acid	FXR	Inflammation/Immunology
Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist .

HY-180221

FXR agonist 14	FXR	Metabolic Disease
FXR agonist 14 (Compound V15) is a partial, selective, orally active *FXR* agonist with an EC₅₀ of 0.67 nM. FXR agonist 14 ameliorates pathological features in high-fat and high-sugar diet-induced MASH mice. FXR agonist 14 shows significant anti-cholestatic liver disease effects .

HY-135399A

Tauro-obeticholic acid sodium	FXR	Inflammation/Immunology
Tauro-obeticholic acid sodium is an active metabolite of Obeticholic acid (HY-12222). Obeticholic acid is a potent, selective and orally active FXR agonist.

HY-182026

FXR agonist 17	FXR G protein-coupled Bile Acid Receptor 1 TNF Receptor Reactive Oxygen Species (ROS)	Inflammation/Immunology
FXR agonist 17 is an orally active, steroidal *FXR* agonist with EC₅₀ values of 42.2 nM (TR-FRET) and 176.4 nM (luciferase reporter assay), respectively. FXR agonist 17 activates TGR5 (EC₅₀ = 2.6 μM) but does not activate hMRGPRX4. FXR agonist 17 exerts anti-inflammatory, hepatoprotective and antifibrotic effects, improves the non-alcoholic steatohepatitis (NAFLD) activity score and reduces the severity of liver fibrosis. FXR agonist 17 can be used for the research of NAFLD, cholestatic liver disease and liver fibrosis .

HY-179703

FXR agonist 15	FXR	Inflammation/Immunology
FXR agonist 15 is a selective, potent and orally active farnesoid X receptor (FXR) agonist with EC₅₀ of 0.76 μM. FXR agonist 15 exhibits no obvious activation on other nuclear receptors including LXRα/β, PXR, PPARα/β/γ, THR-β, with EC₅₀ values all >10 μM. FXR agonist 15 can alleviate steatosis, lobular inflammation, hepatocyte ballooning and liver fibrosis. FXR agonist 15 can be used for the research of nonalcoholic steatohepatitis (NASH) .

HY-100443B

(R,R)-PX20606	FXR Autophagy	Metabolic Disease
(R,R)-PX20606 is a *FXR* agonist with EC₅₀s of 18 and 29 nM for FXR in FRET and M1H assay, respectively.

HY-169192

BAR-2227	FXR	Inflammation/Immunology
BAR-2227 (compound 3a) is a *FXR* agonist and LIFR inhibitor. BAR-2227 can be used to study liver fibrosis and inflammation .

HY-121110

Fexarene	FXR	Metabolic Disease
Fexarene is a potent and selective nonsteroidal Farnesoid X Receptor (FXR) agonist with an EC₅₀ of 36 nM. Fexarene can be used in studies of cholesterol and bile acid metabolism .

HY-183692

FXR agonist 18	FXR G protein-coupled Bile Acid Receptor 1 TNF Receptor Heme Oxygenase (HO) Quinone Reductase Keap1-Nrf2	Cardiovascular Disease Inflammation/Immunology
FXR agonist 18 is an orally active *FXR* agonist, with an EC₅₀ of 10 nM against human FXR and an EC₅₀ of 1360 nM against human TGR5. FXR agonist 18 inhibits inflammatory responses by reducing nitrite production, downregulating the expression of pro-inflammatory genes (Tnf, Adgre1, Cyp8b1, upregulating the expression of FXR, Hmox1, Nqo1, Nrf2, and enhancing antioxidant responses. FXR agonist 18 ameliorates liver fibrosis in mice, exhibits protective effects in mice with cholestatic liver injury, and shows anti-MASH efficacy. FXR agonist 18 can be used in studies of metabolic dysfunction-associated steatohepatitis .

HY-135400S

Glyco-obeticholic acid-d5	FXR	Inflammation/Immunology
Glyco-obeticholic acid-d₅ is the deuterium labeled Glyco-Obeticholic acid. Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist .

HY-117918

ST-1892	FXR	Metabolic Disease Inflammation/Immunology
ST-1892 (compound 14) is a highly potent *FXR* agonist (EC₅₀=7.2 nM) that can be used to study diseases or disorders caused by metabolic inflammation .

HY-111049

GSK8062	FXR	Metabolic Disease
GSK8062 is a farnesoid X receptor (FXR) agonist with activity that improves compound development parameters. Analog 1c of GSK8062 showed a reduction in weight gain and serum glucose levels .

Cat. No.	Product Name	Target	Research Area

HY-A0248BR

Polymyxin B2 (Standard)	Reference Standards Antibiotic Bacterial	Infection
Obeticholic acid (Standard) is the analytical standard of Obeticholic acid. This product is intended for research and analytical applications. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N4067

Isochenodeoxycholic acid isoCDCA	Source Classification	FXR Endogenous Metabolite
Isochenodeoxycholic acid (isoCDCA) is a *FXR* agonist. Isochenodeoxycholic acid activates the activity of FXR and induces the mRNA expression of FXR target genes (Ostβ and Kng1). Isochenodeoxycholic acid serves as a substrate for the liver class I ADH γγ isozyme-mediated 3β-dehydrogenation reaction .

HY-N3431

Kaempferol-7-O-rhamnoside	Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Chimonanthus nitens Oliv. Plants Disease Research Fields Source Classification Calycanthaceae	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-N4294

Arjungenin	Triterpenes Classification of Application Fields Terpenoids Combretaceae Metabolic Disease Terminalia chebula Retz. Plants Disease Research Fields Source Classification	FXR Insecticide
Arjungenin, a pentacyclic triterpenoid compound, is a *FXR* agonist. Arjungenin can improve insulin sensitivity by regulating the function of fat cells. Arjungenin exhibits moderate free radical scavenging activity. Arjungenin has growth inhibitory activity against the insect Spilarctia obliqua. Arjungenin has significant antiviral activity against a series of viruses such as chikungunya Virus (CHIKV) .

HY-N3209

Nelumol A	Ketones, Aldehydes, Acids Tamarindus indica L. Plants Compositae Source Classification	FXR
Nelumol A is a farnesoid X receptor (FXR) agonist .

HY-N3891

Fargesone A	Magnoliaceae Lignans Yulania biondii (Pamp.) D. L. Fu Phenylpropanoids Plants Source Classification	FXR
Fargesone A is a potent and selective *FXR* agonist. Fargesone A shows anti-inflammatory activity .

HY-N10640

Alismanol M	Triterpenes Terpenoids Alisma orinentale (Samuel.) Juz. Plants Alismataceae	FXR
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .

HY-N4294R

Arjungenin (Standard)	Triterpenes Terpenoids Combretaceae Terminalia chebula Retz. Plants Source Classification	Reference Standards FXR Insecticide
Arjungenin (Standard) is the analytical standard of Arjungenin. This product is intended for research and analytical applications. Arjungenin, a pentacyclic triterpenoid compound, is a *FXR* agonist. Arjungenin can improve insulin sensitivity by regulating the function of fat cells. Arjungenin exhibits moderate free radical scavenging activity. Arjungenin has growth inhibitory activity against the insect Spilarctia obliqua. Arjungenin has significant antiviral activity against a series of viruses such as chikungunya Virus (CHIKV).

Cat. No.	Product Name	Chemical Structure

HY-12222S

Obeticholic acid-d5
Obeticholic acid-d₅ is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-135400S

Glyco-obeticholic acid-d5
Glyco-obeticholic acid-d₅ is the deuterium labeled Glyco-Obeticholic acid. Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist .

HY-12365S2

Tauro-obeticholic acid-d5
Tauro-obeticholic acid-d₅ is deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-135399S

Tauro-obeticholic acid-d5 sodium
Tauro-obeticholic acid-d₅ sodium is deuterium labeled Tauro-obeticholic acid sodium (HY-135399A). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-W653920

Tauro 6-ethlchenodeoxycholic acid-d5(sodium）
Tauro 6-ethlchenodeoxycholic acid-d₅ sodium is deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-12222S1

Obeticholic acid-d4-1
Obeticholic Acid-d₄ is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-135400S2

Glyco-obeticholic acid-d4
Glyco-obeticholic acid-d₄ is the deuterium labeled Glyco-obeticholic acid (HY-135400). Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist .

HY-135399S2

Tauro-obeticholic acid-d4
Tauro-obeticholic acid-d₄ is the deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks